BAFNAPHPharmaceuticals
Bafna Pharmaceuticals Ltd — Cash Flow Statement
₹109.34
-4.38%
Bafna Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 0.28 Cr | -6.36 Cr | -3.27 Cr | 2.19 Cr | — |
| Capital Expenditure | -21.86 Cr | -15.85 Cr | -8.22 Cr | -7.54 Cr | — |
| End Cash Position | 3.43 Cr | 1.40 Cr | 7.81 Cr | 0.17 Cr | — |
| Beginning Cash Position | 1.40 Cr | 7.81 Cr | 0.17 Cr | 1.80 Cr | — |
| Changes In Cash | 2.04 Cr | -6.41 Cr | 7.64 Cr | -1.63 Cr | — |
| Financing Cash Flow | 1.06 Cr | -0.85 Cr | 10.18 Cr | -4.81 Cr | — |
| Interest Paid Cff | -2.75 Cr | -2.31 Cr | -1.69 Cr | -0.09 Cr | — |
| Net Issuance Payments Of Debt | 3.81 Cr | 1.47 Cr | 11.86 Cr | -4.73 Cr | — |
| Net Long Term Debt Issuance | 3.81 Cr | 1.47 Cr | 11.86 Cr | -4.73 Cr | — |
| Investing Cash Flow | -21.16 Cr | -15.05 Cr | -7.49 Cr | -6.54 Cr | — |
| Net Other Investing Changes | 0.50 Cr | 0.50 Cr | 0.50 Cr | 0.98 Cr | — |
| Interest Received Cfi | 0.14 Cr | 0.12 Cr | 0.03 Cr | 0.01 Cr | — |
| Net Investment Purchase And Sale | -5000.00 | 0.00 | — | — | — |
| Purchase Of Investment | -5000.00 | 0.00 | — | — | — |
| Net Intangibles Purchase And Sale | 0.00 | -0.27 Cr | -1.50 Cr | 0.00 | — |
| Purchase Of Intangibles | 0.00 | -0.27 Cr | — | — | — |
| Net PPE Purchase And Sale | -21.80 Cr | -15.41 Cr | -6.52 Cr | -7.54 Cr | — |
| Sale Of PPE | 0.06 Cr | 0.17 Cr | 0.20 Cr | 0.00 | — |
| Purchase Of PPE | -21.86 Cr | -15.58 Cr | -6.72 Cr | -7.54 Cr | — |
| Operating Cash Flow | 22.14 Cr | 9.48 Cr | 4.95 Cr | 9.73 Cr | — |
| Taxes Refund Paid | 0.35 Cr | -0.17 Cr | -0.13 Cr | -0.17 Cr | — |
| Change In Working Capital | 7.55 Cr | -5.28 Cr | -14.42 Cr | -0.80 Cr | — |
| Change In Other Current Liabilities | 1.54 Cr | 1.51 Cr | 0.45 Cr | 0.01 Cr | — |
| Change In Other Current Assets | 3.72 Cr | -1.89 Cr | -1.21 Cr | -3.56 Cr | — |
| Change In Payable | -4.48 Cr | 6.96 Cr | 16.06 Cr | 12.22 Cr | — |
| Change In Inventory | 1.18 Cr | -7.42 Cr | -1.94 Cr | -4.84 Cr | — |
| Change In Receivables | 5.56 Cr | -4.87 Cr | -27.00 Cr | -6.19 Cr | — |
| Other Non Cash Items | 4.61 Cr | 2.06 Cr | 1.67 Cr | 82000.00 | — |
| Provisionand Write Offof Assets | 0.50 Cr | 0.53 Cr | 0.77 Cr | 0.00 | — |
| Depreciation And Amortization | 4.89 Cr | 5.00 Cr | 5.33 Cr | 5.49 Cr | — |
| Depreciation | 4.89 Cr | 5.00 Cr | 5.33 Cr | 5.49 Cr | — |
| Gain Loss On Sale Of PPE | 0.07 Cr | -0.07 Cr | -0.20 Cr | 0.00 | — |
| Net Income From Continuing Operations | 4.15 Cr | 7.35 Cr | 11.62 Cr | 5.19 Cr | — |
| Issuance Of Capital Stock | — | — | — | 0.00 | 0.00 |
| Net Other Financing Charges | — | — | — | 0.98 Cr | — |
| Net Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Common Stock Issuance | — | — | — | 0.00 | 0.00 |
| Net Short Term Debt Issuance | — | — | — | -9.80 Cr | 9.87 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | — | -19000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bafna Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.